



# The efficacy of $^{99m}\text{Tc}$ -rituximab as a tracer for sentinel lymph node biopsy in cutaneous melanoma patients

Jiayong Liu<sup>1#</sup>, Zhichao Tan<sup>1#</sup>, Ruifeng Xue<sup>1#</sup>, Zhengfu Fan<sup>1</sup>, Chujie Bai<sup>1</sup>, Shu Li<sup>1</sup>, Tian Gao<sup>1</sup>, Lu Zhang<sup>1</sup>, Zhiwei Fang<sup>1</sup>, Lu Si<sup>2</sup>

<sup>1</sup>Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital and Institute, Beijing, China; <sup>2</sup>Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China

*Contributions:* (I) Conception and design: Z Tan, Z Fan, R Xue; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: None; (V) Data analysis and interpretation: S Li, T Gao; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

<sup>#</sup>These authors contributed equally to this work.

*Correspondence to:* Jiayong Liu. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital & Institute, 52 Fucheng Rd., Beijing 100142, China. Email: liujiayong\_doc@163.com; Lu Si. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, 52 Fucheng Rd., Beijing 100142, China. Email: silu15\_silu@126.com.

**Background:** The sentinel lymph node (SLN) status is a vital prognostic factor for malignant melanoma (MM) patients. There is increasing evidence that a radioactive agent, rather than its combination with blue dye, is sufficient for a SLN biopsy (SLNB). Thus, we discussed the efficacy of  $^{99m}\text{Tc}$ -rituximab as a tracer in MM patients.

**Methods:** A total of 502 consecutive patients with MM who underwent SLNB were enrolled in this study. All participants were peritumorally injected with  $^{99m}\text{Tc}$ -rituximab before imaging, and scanned with single-photon emission computed tomography-computed tomography (SPECT-CT) to detect the number and location of the SLN. A gamma detection probe was employed to detect radioactive SLNs in operation. Follow up was conducted to observe whether nodal or distant recurrence occurred.

**Results:** The SLNs were successfully imaged via SPECT-CT and harvested from all 502 participants. No drainage tube was indwelled and 32 (6.3%) participants experienced the following complications: seroma (n=26, 5.2%), wound infections or lymphangitis (n=6, 1.2%), sensory nerve injuries (n=4, 0.8%). There were 380 patients who were diagnosed as SLN-negative and 122 (24.2%) were SLN-positive. A total of 85 SLN-positive patients received complete lymph node dissection, and 28 (32.9%) had additional positive lymph nodes. During a median follow-up of 24 months, 28 participants were found to have a false negative (FN) SLN. The FN rate was 18.7%. A higher T stage was a predictive factor for FN [odds ratio (OR) 1.77; P<0.05]. There was no significant difference in the positive or FN rate between the acral and cutaneous groups.

**Conclusions:** The radiopharmaceutical  $^{99m}\text{Tc}$ -rituximab could be employed as a simple and safe tracer in acral and cutaneous melanoma SLN biopsies.

**Keywords:** Melanoma; sentinel node biopsy;  $^{99m}\text{Tc}$ -rituximab; false negative; radioactive tracer

Submitted Nov 22, 2021. Accepted for publication Jan 20, 2022.

doi: 10.21037/atm-21-6890

View this article at: <https://dx.doi.org/10.21037/atm-21-6890>

## Introduction

A sentinel lymph node biopsy (SLNB) is a vital procedure in melanoma patients as recommended by the National Comprehensive Cancer Network (NCCN) guideline (1). It is a key staging procedure for patients with clinical stage I-II melanoma according to the presence or absence of nodal metastasis. The available evidence strongly supports the sentinel lymph node (SLN) status as the most powerful independent factor for predicting survival (2-4). Accurate staging is generally accepted as the basis for counseling, therapeutic decision-making, and prognostication in melanoma. Depending on a variety of factors, 5–40% patients will be detected as SLN-positive (1,2,5-8). The commonly acknowledged risk factors of a positive SLN include the Clark level, mitotic rate, ulceration, lymphovascular invasion, anatomic site, tumor infiltrating lymphocytes, and primary tumor thickness (1,3,9-14). Compared to Caucasian patients, Chinese melanoma patients tend to be associated with a longer delay to diagnosis and a higher proportion of T-stage III–IV status (15,16). Therefore, an accurate SLNB procedure is particularly essential for clinical work.

The NCCN-recommended technique for SLNB consists of preoperative dynamic lymphoscintigraphy, intraoperative identification using isosulfan blue or methylene blue dye, and a gamma probe to detect radiolabeled lymph nodes (1). However, recent studies have increasingly indicated that the use of blue dye is associated with a negative outcome. Ranson *et al.* performed SLNB in 537 patients using both a  $^{99m}\text{Tc}$  radiocolloid and blue dye, and reported that if the blue dye was excluded and only hot nodes were harvested, it would only result in a 5% reduction of dissected nodes without any compromise in the sensitivity of the test (17). van der Ploeg *et al.* retrospectively assessed 681 patients, and discovered that a blue, nonradioactive sentinel node was removed in only 0.9% of patients (18). There was a minor reduction in the collected nodes; however, there are other negative impacts of using blue dye, including anaphylaxis [ranging from 0.1% to 2.7% (19-21)], prolonged cutaneous staining (22), and its contraindication in pregnant women. In 2013, the US Food and Drug Administration approved Lymphoseek ( $^{99m}\text{Tc}$ -tilmanocept) as a radiotracer for detecting SLN in breast and melanoma patients (23). Inspired by this invention, we developed  $^{99m}\text{Tc}$ -labeled rituximab as a novel radiotracer. The accuracy and specificity of this tracer has been tested and verified in breast cancer patients in our institution, with a sensitivity

97.4% and specificity of 100% (24,25). But its efficacy in melanoma has not been proved.

Rituximab is an antibody that specifically targets the CD20 molecules expressed in B lymphocytes. Theoretically,  $^{99m}\text{Tc}$ -rituximab can combine with B lymphocytes in the first lymph node on the lymph circulating route, which is the precise definition of “sentinel lymph node”, and avoids imaging of second-tier lymph nodes. Because this radio tracer can be detected within at least 6–8 h post-injection, surgeons are guaranteed to have sufficient time during the operation. Besides, the side effects of blue dye, such as anaphylaxis and skin staining, can be avoided. In this study, we aimed to report the feasibility, effectiveness, and safety of using  $^{99m}\text{Tc}$ -rituximab for the clinical testing of SLN in melanoma.

We present the following article in accordance with the STROBE reporting checklist (available at <https://atm.amegroups.com/article/view/10.21037/atm-21-6890/rc>).


## Methods

### Patients

From February 2009 to March 2019, a total of 502 consecutive patients with melanoma underwent a biopsy at the Department of Bone and Soft Tissue Sarcoma of Peking University Cancer Hospital. The indications for SLNB included: (I) primary melanoma, Breslow thickness  $\geq 1$  mm, or Breslow thickness  $< 1$  mm and with other adverse features (e.g., ulceration, high mitotic rate, and lymphovascular invasion); (II) clinically negative lymph nodal basin (examined by palpation and ultrasound); (III) absence of distant metastasis [confirmed by routine physical examination, chest and abdominal computed tomography (CT) scan, or positron emission tomography (PET)-CT]; and (IV) feasibility for anesthesia. All procedures performed in this study involving human participants were in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by institutional ethics committee of Peking University Cancer Hospital and informed consent was taken from all the patients.

### SLNB

The radiotracer was prepared as described in a previous study (24). The radiotracer solution was approximately 74 MBq/mL with saline. All participants were administered with peritumoral intradermal injections of  $^{99m}\text{Tc}$ -rituximab



**Figure 1** Detecting and harvesting the  $^{99m}\text{Tc}$ -rituximab marked SLN. (A) The lymphoscintigraphy of location (arrow) and number of SLN; (B) a minimal incision was made to acquire the SLN. SLN, sentinel lymph node.

(10.0 MBq, 0.2 mL) on the same day or the day prior to the operation. Planar lymphoscintigraphy was then acquired by a single-photon emission computed tomography-computed tomography (SPECT-CT) system (E. Cam; Siemens, Erlangen, Germany) to determine the location and number of SLNs (*Figure 1A*). During the operation, the precise position of the SLNs was located using a handheld gamma detection probe (Neoprobe, Dublin, OH, USA or Crystal Photonics, Berlin, Germany) before the surgical incision, after which a minimal incision (2–4 cm) was performed (*Figure 1B*). All radioactive nodes with a counting rate  $\geq 10\%$  of the hottest node were removed.

### Pathology

During routine pathologic examination, SLNs were cut along the major axis, formalin-fixed, embedded in paraffin, and stained with hematoxylin and eosin (H&E). Intraoperative frozen section investigations were not performed. Paraffin-embedded specimens were examined by light microscopy at magnifications of  $\times 40$  and  $\times 200$ . Additional immunohistochemical (IHC) staining (S100, HMB-45 and Melan-A) was used for suspicious cases identified with H&E. All negative SLNs with local nodal recurrence were retrospectively reviewed by an experienced pathologist (Lai). Additional serial sectioning (at a 2-mm interval) was performed on all of the reviewed SLN biopsy specimens, and doubtful cases were stained for IHC.

### Statistical analysis

For the statistical analysis of the data, contingency tables were analyzed using a  $\chi^2$  test. For the survival analysis, a Kaplan-Meier estimator was used with generalized Wilcoxon and log-rank tests for bivariate comparisons. In the analysis of risk factors, binary logistic regression was deployed. The disease-free survival (DFS) time was calculated from the time of the primary diagnosis to the time point of disease recurrence or death due to any reason. The overall survival (OS) time was calculated from the time of primary diagnosis to the time point of death for any reason. All statistical analyses were performed using SPSS 25.0 (SPSS Inc., Chicago, IL, USA). The differences between groups were considered to be significant for P values  $< 0.05$ .

### Results

A total of 502 patients were enrolled in this study, among whom 239 were men and 263 were women. Acral malignant melanoma (MM) and T3–4 stage patients comprised the majority, accounting for 74.5% (374 patients) and 59.4% (298 patients), respectively (*Table 1*). The SPECT-CT scanning was omitted in 3 participants due to patient rejection or an operation being pressed for time. We detected SLNs in the remaining 499 participants (100%). The imaging time ranged from 0.33 to 16 h (median: 1 h).

**Table 1** Characteristics of patients undergoing SLN biopsy

Characteristics	Total patients	Number of SLN-positive patients (%)
Patient (n)	502	122 (24.3)
Male	239	58 (24.3)
Female	263	64 (24.3)
Age [median]	58.0 [8–86]	60.0 [8–80]
Location		
Acral MM	374	87 (23.3)
Upper limb	91	15 (16.5)
Lower limb	283	72 (25.4)
Cutaneous MM	128	35 (27.3)
Upper limb	21	5 (23.8)
Lower limb	58	13 (22.4)
Trunk	45	16 (35.6)
Others (perineum, head, etc.)	4	1 (25.0)
T stage		
Tis	5	0 (0.0)
1	65	9 (13.8)
1a	46	6 (13.0)
1b	18	3 (16.7)
1x	1	0 (0.0)
2	95	15 (15.8)
2a	63	10 (15.9)
2b	28	5 (17.9)
2x	4	0 (0.0)
3	137	37 (27.0)
3a	70	21 (30.0)
3b	63	15 (23.8)
3x	4	1 (25.0)
4	161	52 (32.3)
4a	47	12 (25.5)
4b	108	37 (34.3)
4x	6	3 (50.0)
NA	33	9 (27.3)

**Table 1** (continued)**Table 1** (continued)

Characteristics	Total patients	Number of SLN-positive patients (%)
Ulceration		
Positive	216	58 (26.9)
Negative	255	53 (20.8)
NA	31	11 (35.5)
Lymphovascular invasion		
Positive	27	9 (33.3)
Negative	365	91 (25.2)
NA	110	22 (20.0)
Clark		
I	3	0 (0.0)
II	11	3 (27.3)
III	41	6 (14.6)
IV	157	35 (22.3)
V	53	16 (30.2)
NA	237	62 (26.2)

SLN, sentinel lymph node; NA, not available; MM, malignant melanoma.

The number of imaged SLNs ranged from 1–8 (median 1). During the operation, SLNs were successfully harvested from all participants, including the 3 patients without SPECT-CT results. The average number of harvested SLN was 2.75.


Complications were observed in 32 patients (6.3%): 26 were seroma (5.2%), 6 were wound infections or lymphangitis (1.2%), and 4 were sensory nerve injuries (0.8%). The inguinal region was a high-risk region for SLNB complications compared to the axilla and neck (Table 2). There were 19 (73.1%) participants with seroma that did not require any intervention, and the remaining 7 (26.9%) participants recovered well after suctioning fluid with a syringe. Those with a wound infection or lymphangitis were treated with antibiotics. Participants with sensory nerve injuries were observed and the symptoms were fully or partially relieved within 6 months. No drainage tube needed to be indwelled, and no second operation was performed.

A total of 112 participants were diagnosed as SLN-

**Table 2** Complications after SLNB

Complications	N (%)	P value
Total patients with complications	32/502 (6.3)	
Seroma	26 (5.2)	
Wound infection	6 (1.2)	
Sensory nerve injury	4 (0.8)	
Location		
Inguina	30/387	P<0.05 ( $\chi^2$ test)
Axilla	2/112	
Neck	0/3	

SLNB, sentinel lymph node biopsy.



**Figure 2** The OS and DFS of SLN-negative and SLN-positive patients. The mean DFS and OS of the SLN-negative group was 74.4 and 106.1 months. The mean DFS and OS of the SLN-positive group was 28.2 and 67.2 months. OS, overall survival; SLN, sentinel lymph node; DFS, disease-free survival.

positive after a pathological examination, in which 74 had only 1 positive SLN, 27 had 2 positive SLNs, and 11 had 3 or more positive SLNs. The SLN positive rates of the acral and cutaneous groups were not significantly different (23.3% vs. 27.3%;  $P=0.40$ ). A total of 85 patients received a complete lymph node dissection. Additional positive lymph nodes (non-SLN positive) were discovered in 28 (32.9%) patients. There were 16 (57.1%) participants who had only 1 non-SLN positive lymph node, 5 (17.9%) had 2 non-SLNs positive lymph nodes, and 7 (25.0%) had 3 nodes or more.

A total of 390 patients were initially diagnosed to be SLN-negative. We followed these patients for up to 140 months (3–40 months; median: 24.0 months). There were 44 patients who exhibited local nodal basin recurrence. After a pathological and medical history review, 10 participants were found to be initially misdiagnosed as SLN-negative, and 6 participants had in-transit recurrence before nodal basin metastasis. After these 16 participants had been excluded, 28 participants were confirmed to be false-negative (FN). The FN rate was defined as the proportion of patients with nodal recurrences after negative SLNB in the patients with nodal involvement. The failure rate was defined as the number of FN patients divided by the total number of SLN-negative patients. Based on this definition, the FN rate of our tracer was 18.7%, and the failure rate was 7.2%.

After pathological review, we increased the number of SLN-positive patients from 112 (22.3%) to 122 (24.2%), and the number of SLN-negative patients was amended to 380. We then compared the survival rate between the 2 groups. The mean DFS and OS of the SLN-negative group was 74.4 months [95% confidence interval (CI): 67.0 to 81.9] and 106.1 months (95% CI: 103.2 to 109.0), respectively. The mean DFS and OS of the SLN-positive group was 28.2 months (95% CI: 22.8 to 33.7) and 67.2 (95% CI: 59.2 to 75.1). Statistical differences were identified between the 2 groups regarding both DFS and OS rates ( $P<0.05$ ) (Figure 2). These results confirmed that the SLN status was a strong predictor of survival.

We further explored the risk factors of FN status. age, gender, T stage, ulceration, Clark stage, mitosis rate, lymphovascular invasion, and primary lesion location (acral or non-acral) were taken into account in the analysis. The FN group was compared with SLN-negative group and SLN-positive group. The results showed that T stage was the only predicting factor for the FN group compared with


**Table 3** Analysis of predicting factors of FN

	FN	SLN-negative	SLN-positive	P value (FN vs. SLN-negative)	P value (FN vs. SLN-positive)
Patient(n)	28	352	122		
Male	14	167	58	0.79	0.81
Female	14	185	64		
Age [median]	60.0 [27–84]	58.0 [20–86]	60.0 [8–80]	0.91	0.95
Location				0.33	0.72
Acral MM	19	268	87		
Cutaneous MM	9	84	35		
T stage				0.01	0.75
Tis	0	5	0		
1	0	56	9		
2	5	76	15		
3	8	92	37		
4	12	97	52		
NA	3	26	9		
Ulceration				0.64	0.70
Positive	13	145	58		
Negative	14	188	53		
NA	1	19	11		
Lymphovascular invasion				0.32	0.84
Positive	3	15	9		
Negative	20	254	91		
NA	5	83	22		
Clark				0.42	0.98
I	0	3	0		
II	0	8	3		
III	0	31	6		
IV	6	110	35		
V	1	33	16		
NA	21	164	62		

FN, false negative; SLN, sentinel lymph node; MM, malignant melanoma; NA, not available.

the SLN-negative group (OR: 1.77; 95% CI: 1.12 to 2.78;  $P=0.01$ ). Acral or cutaneous subtype was not a risk factor in either comparison (FN vs. SLN-negative,  $P=0.33$ ; FN vs. SLN-positive,  $P=0.72$ ). There were no differences between the FN group and SLN-positive group in the listed risk

factors (Table 3). The median time to nodal basin recurrence in the FN group was 10.6 months. Although misdiagnosed, the OS of FN group (mean: 94.9 months; 95% CI: 84.8 to 104.9) was not statistically different from the OS of the SLN-positive group ( $P=0.17$ ) (Figure 3).



**Figure 3** The OS of FN and SLN-positive patients. The OS of FN group was not statistically different from the OS of the SLN-positive group. OS, overall survival; FN, false negative; SLN, sentinel lymph node; DFS, disease-free survival.

## Discussion

In the present study, SLN was detected in 100% of patients by SPECT-CT, and none of the participants failed the SLN biopsy. The mean number of harvested SLNs was 2.75. The operation procedure was simplified because the location and number of SLN could be identified based on the SPECT-CT report.  $^{99m}\text{Tc}$ -rituximab has been deployed successfully as a tracer in breast cancer patients. In a study about evaluation of  $^{99m}\text{Tc}$ -rituximab in breast cancer published in 2016, the success rate of lymphoscintigraphy and SLNB was 98.8% and 99.9% (24). Our result is in accordance with the previous study. In addition, by using the  $\gamma$ -detector to accurately locate the SLN before incision, surgeons could minimize the surgical wound and shorten the operation time. Without a drainage tube, only 6.3% patients experienced postoperative complications, which was a relatively low rate compared to that of other studies (5–10%) (26–32). Most of the complications were mild and recovered following conservative treatment. Complications were more common in groin SLNB than in the axilla and neck. These results were similar to those of previous studies.

In this study, SLN was a strong predictor of both OS and DFS. These results complied with previous studies, and showed that the tracer,  $^{99m}\text{Tc}$ -rituximab, could distinguish the SLN-positive patients from the entire population.

After revision, 122 participants (24.2%) were diagnosed as SLNB-positive, 85 of whom received a complete lymph node dissection (CLND). A total of 28 participants (32.9%) were found to have non-SLN positive lymph nodes. The non-SLN positive rate was much higher compared with

the NCCN guidelines and the findings of other studies (12–32%, average 20%) (1,33–37). These differences may be attributed to a higher proportion of acral melanoma and a higher number of T3–4 patients in our group. Previous studies have demonstrated that Asian melanoma patients tend to be affected by the acral subtype, have a more advanced stage at the time of diagnosis, and face a poorer prognosis (16,38–42). These results may imply that CLND is still a necessary procedure for SLNB-positive patients with acral melanoma; thus, further randomized clinical trials are warranted.

A total of 10 participants were found to be SLN-positive following a pathological review. The NCCN guidelines for cutaneous melanoma recommended that large lymph nodes might be bisected or sliced at 2-mm intervals (1). Previously, the routine at our center was to bisect the SLN along the longitudinal axis. In the 10 misdiagnosed participants, 4 had micrometastasis on the marginal sinus of the previous SLN pathology slide; 5 had no metastasis on the primary SLN pathology slide, but after additional sectioning, micrometastasis was discovered on high magnification; and 1 had suspicious metastasis after additional sectioning, which was confirmed by IHC staining. These results prompted that 2-mm interval sectioning, instead of a bisection, may be an essential procedure in melanoma SLN pathology. The IHC staining should be applied when suspicious lesions are observed. We have negotiated with our pathologists and agreed that the 2-mm interval sectioning should be adopted as a standard procedure afterwards. We would like to observe whether the FN rate could be further lowered by additional sectioning.

The FN rate in our study was 18.7%, which was a reasonable level compared with that of previous studies (7–20%) (5,13,35,36,43–47). In our analysis, a higher T stage was a predictive factor for the FN status. These results were in accordance with the findings of a study conducted by Nowecki, who analyzed 1,207 MM patients and found that primary tumor thickness, primary tumor ulceration, Clark stage IV/V, and histological nodular melanoma were strongly associated with FN occurrence (45). The risk factors (e.g., ulceration, Clark stage, and histological type) were not significant in this study. This might have contributed to a relatively small number of FN patients (28 *vs.* 57; Nowecki study). The OS between the FN group and SLN-positive group was not significant, which indicated that despite an initial misdiagnosis, the survival of FN group patients would not be impaired as long as close follow-up was ensured in each patient (48–50).

## Conclusions

The findings of this study suggested that <sup>99m</sup>Tc-rituximab may be employed as a simple and safe tracer in a melanoma SLN biopsy.

## Acknowledgments

*Funding:* This study was supported by the Science Foundation of Peking University Cancer Hospital (08-29).

## Footnote

*Reporting Checklist:* The authors have completed the STROBE reporting checklist. Available at <https://atm.amegroups.com/article/view/10.21037/atm-21-6890/rc>

*Data Sharing Statement:* Available at <https://atm.amegroups.com/article/view/10.21037/atm-21-6890/dss>

*Conflicts of Interest:* All authors have completed the ICMJE uniform disclosure form (available at <https://atm.amegroups.com/article/view/10.21037/atm-21-6890/coif>). All authors report that this study was supported by the Science Foundation of Peking University Cancer Hospital. The authors have no other conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in this study involving human participants were in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by institutional ethics committee of Peking University Cancer Hospital and informed consent was taken from all the patients.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. Coit DG, Thompson JA, Albertini MR, et al. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2019;17:367-402.
2. Ferrone CR, Panageas KS, Busam K, et al. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. *Ann Surg Oncol* 2002;9:637-45.
3. Johnson TM, Sondak VK, Bichakjian CK, et al. The role of sentinel lymph node biopsy for melanoma: evidence assessment. *J Am Acad Dermatol* 2006;54:19-27.
4. Doting MH, Hoekstra HJ, Plukker JT, et al. Is sentinel node biopsy beneficial in melanoma patients? A report on 200 patients with cutaneous melanoma. *Eur J Surg Oncol* 2002;28:673-8.
5. Staius Muller MG, van Leeuwen PA, de Lange-De Klerk ES, et al. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma. *Cancer* 2001;91:2401-8.
6. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. *J Clin Oncol* 2009;27:6199-206.
7. Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. *Ann Surg Oncol* 2004;11:247-58.
8. Rousseau DL Jr, Ross MI, Johnson MM, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. *Ann Surg Oncol* 2003;10:569-74.
9. Bedrosian I, Faries MB, Guerry D 4th, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. *Ann Surg Oncol* 2000;7:262-7.
10. Azimi F, Scolyer RA, Rumcheva P, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. *J Clin Oncol* 2012;30:2678-83.
11. Speijers MJ, Bastiaannet E, Sloot S, et al. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients.



- Ann Surg Oncol 2015;22:2978-87.
12. Munsch C, Lauwers-Cances V, Lamant L, et al. Breslow thickness, clark index and ulceration are associated with sentinel lymph node metastasis in melanoma patients: a cohort analysis of 612 patients. *Dermatology* 2014;229:183-9.
  13. Lima Sánchez J, Sánchez Medina M, García Duque O, et al. Sentinel lymph node biopsy for cutaneous melanoma: a 6 years study. *Indian J Plast Surg* 2013;46:92-7.
  14. Cavanaugh-Hussey MW, Mu EW, Kang S, et al. Older Age is Associated with a Higher Incidence of Melanoma Death but a Lower Incidence of Sentinel Lymph Node Metastasis in the SEER Databases (2003-2011). *Ann Surg Oncol* 2015;22:2120-6.
  15. Chi Z, Li S, Sheng X, et al. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. *BMC Cancer* 2011;11:85.
  16. Lee HY, Chay WY, Tang MB, et al. Melanoma: differences between Asian and Caucasian patients. *Ann Acad Med Singap* 2012;41:17-20.
  17. Ranson JM, Pantelides NM, Pandit DG, et al. Sentinel lymph node biopsy in melanoma: Which hot nodes should be harvested and is blue dye really necessary? *J Plast Reconstr Aesthet Surg* 2018;71:1269-73.
  18. van der Ploeg IM, Madu MF, van der Hage JA, et al. Blue dye can be safely omitted in most sentinel node procedures for melanoma. *Melanoma Res* 2016;26:464-8.
  19. Leong SP, Donegan E, Heffernon W, et al. Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma. *Ann Surg Oncol* 2000;7:361-6.
  20. Bézu C, Coutant C, Salengro A, et al. Anaphylactic response to blue dye during sentinel lymph node biopsy. *Surg Oncol* 2011;20:e55-9.
  21. Clarke SA, Molajo A, Powell BW. Incidence of adverse reactions to patent blue dye in melanoma sentinel node biopsy: a major UK centre experience. *J Plast Reconstr Aesthet Surg* 2013;66:1299-300.
  22. Ariyan S, Ariyan C, Farber LR, et al. Reliability of identification of 655 sentinel lymph nodes in 263 consecutive patients with malignant melanoma. *J Am Coll Surg* 2004;198:924-32.
  23. Wallace AM, Han LK, Povoski SP, et al. Comparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials. *Ann Surg Oncol* 2013;20:2590-9.
  24. Li N, Wang X, Lin B, et al. Clinical Evaluation of 99mTc-Rituximab for Sentinel Lymph Node Mapping in Breast Cancer Patients. *J Nucl Med* 2016;57:1214-20.
  25. Wang J, Fan T, He Y, et al. 99mTc-rituximab as a tracer for sentinel lymph node biopsy in breast cancer patients: a single-center analysis. *Breast Cancer Res Treat* 2018;168:365-70.
  26. Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. *Ann Surg Oncol* 2003;10:676-80.
  27. Chakera AH, Drzewiecki KT, Eigtved A, et al. Sentinel node biopsy for melanoma: a study of 241 patients. *Melanoma Res* 2004;14:521-6.
  28. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. *Ann Surg* 2005;242:302-11; discussion 311-3.
  29. Gad D, Høilund-Carlsen PF, Bartram P, et al. Staging patients with cutaneous malignant melanoma by same-day lymphoscintigraphy and sentinel lymph node biopsy: a single-institutional experience with emphasis on recurrence. *J Surg Oncol* 2006;94:94-100.
  30. Read RL, Pasquali S, Haydu L, et al. Quality assurance in melanoma surgery: The evolving experience at a large tertiary referral centre. *Eur J Surg Oncol* 2015;41:830-6.
  31. Wasserberg N, Tulchinsky H, Schachter J, et al. Sentinel-lymph-node biopsy (SLNB) for melanoma is not complication-free. *Eur J Surg Oncol* 2004;30:851-6.
  32. de Vries M, Vonkeman WG, van Ginkel RJ, et al. Morbidity after axillary sentinel lymph node biopsy in patients with cutaneous melanoma. *Eur J Surg Oncol* 2005;31:778-83.
  33. Kettlewell S, Moyes C, Bray C, et al. Value of sentinel node status as a prognostic factor in melanoma: prospective observational study. *BMJ* 2006;332:1423.
  34. Kim C, Economou S, Amatruda TT, et al. Prognostic significance of microscopic tumor burden in sentinel lymph node in patients with cutaneous melanoma. *Anticancer Res* 2015;35:301-9.
  35. Rutkowski P, Szydłowski K, Nowecki ZI, et al. The long-term results and prognostic significance of cutaneous melanoma surgery using sentinel node biopsy with triple technique. *World J Surg Oncol* 2015;13:299.
  36. Bertolli E, Macedo MP, Pinto CA, et al. Metastatic area ratio can help predict nonsentinel node positivity in melanoma patients. *Melanoma Res* 2016;26:42-5.
  37. Shaw HM, Thompson JF. Frequency of nonsentinel

- lymph node metastasis in melanoma. *Ann Surg Oncol* 2002;9:934;author reply 934-5.
38. Lv J, Dai B, Kong Y, et al. Acral Melanoma in Chinese: A Clinicopathological and Prognostic Study of 142 cases. *Sci Rep* 2016;6:31432.
  39. Kim HJ, Seo JW, Roh MS, et al. Clinical features and prognosis of Asian patients with acral lentiginous melanoma who have nodal nevi in their sentinel lymph node biopsy specimen. *J Am Acad Dermatol* 2018;79:706-13.
  40. Johnson DS, Yamane S, Morita S, et al. Malignant melanoma in non-Caucasians: experience from Hawaii. *Surg Clin North Am* 2003;83:275-82.
  41. Luk NM, Ho LC, Choi CL, et al. Clinicopathological features and prognostic factors of cutaneous melanoma among Hong Kong Chinese. *Clin Exp Dermatol* 2004;29:600-4.
  42. Zhang M, Zhang N. Clinical and prognostic factors in 98 patients with malignant melanoma in China. *J Int Med Res* 2017;45:1369-77.
  43. Staius Muller MG, van Leeuwen PA, van Diest PJ, et al. No indication for performing sentinel node biopsy in melanoma patients with a Breslow thickness of less than 0.9 mm. *Melanoma Res* 2001;11:303-7.
  44. Borgognoni L, Urso C, Vaggelli L, et al. Sentinel node biopsy procedures with an analysis of recurrence patterns and prognosis in melanoma patients: technical advantages using computer-assisted gamma probe with adjustable collimation. *Melanoma Res* 2004;14:311-9.
  45. Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, et al. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. *Ann Surg Oncol* 2006;13:1655-63.
  46. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. *N Engl J Med* 2014;370:599-609.
  47. Yamamoto M, Fisher KJ, Wong JY, et al. Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma. *Cancer* 2015;121:1628-36.
  48. Satzger I, Meier A, Zapf A, et al. Is there a therapeutic benefit of complete lymph node dissection in melanoma patients with low tumor burden in the sentinel node? *Melanoma Res* 2014;24:454-61.
  49. Bamboat ZM, Konstantinidis IT, Kuk D, et al. Observation after a positive sentinel lymph node biopsy in patients with melanoma. *Ann Surg Oncol* 2014;21:3117-23.
  50. van der Ploeg AP, van Akkooi AC, Rutkowski P, et al. Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection. *Br J Surg* 2012;99:1396-405.
- (English Language Editor: J. Jones)

**Cite this article as:** Liu J, Tan Z, Xue R, Fan Z, Bai C, Li S, Gao T, Zhang L, Fang Z, Si L. The efficacy of <sup>99m</sup>Tc-rituximab as a tracer for sentinel lymph node biopsy in cutaneous melanoma patients. *Ann Transl Med* 2022;10(2):95. doi: 10.21037/atm-21-6890